Whitepaper: The effect of humidity on tablet surfaces containing different types of superdisintegrants
This whitepaper studies the effect of humidity on tablet surfaces containing different types of super disintegrants.
List view / Grid view
This whitepaper studies the effect of humidity on tablet surfaces containing different types of super disintegrants.
Superdisintegrants are categorised by their mechanism of action such as wicking, swelling or shape recovery. In this study, the performance of disintegrants from each of these groups was tested in an insoluble, hydrophobic tablet formulation.
Watch how PROSOLV® EASYtab, the all-in-one excipient composite, offers superior disintegration for your tablet formulations.
Discover JRS PHARMA's industry leading manufacturing network for Microcrystalline Cellulose.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
Robust and sensitive, the PyroMAT® Monocyte Activation Test system is a non-animal based method for the detection of endotoxin and non-endotoxin pyrogens. Download our studies
The European Commission has granted marketing authorisation to Celltrion's Remsima (infliximab, CT-P13) subcutaneous formulation.
Quality control testing instrumentation solutions for GMP manufacturing. From raw materials QC through production QC and final product QC.
This whitepaper from Beckman Coulter discusses GMP Cleanrooms Classification and Routine Environmental Monitoring.
This whitepaper from Beckman Coulter explores GMP cleanroom routine environmental monitoring and data integrity.
Maintaining Data Integrity. Did you know that lack of data integrity has been a top reason for FDA Drug GMP warning letters?
The new MET ONE 3400+ Series PortableAirborne Particle Counter automates environmental monitoring for GMP cleanroom compliance.
This article explores what pharmaceutical companies could be doing to promote injectable biosimilar approval and consumer uptake.
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
Scientists unveil their model, which other researchers can use to test the injectability of their drug delivering microparticle designs in silico.